Brain

Article	Citations
Reply: Is postural tachycardia syndrome a psychogenic disorder?; Notes on establishing fear conditioning as causal in the postural orthostatic tachycardia syndrome; Patients with POTS fear that data o	360
Clinical dimensions along the non-fluent variant primary progressive aphasia spectrum	319
Impaired ribosome-associated quality control of C9orf72 arginine-rich dipeptide-repeat proteins	316
Thalamostriatal disconnection underpins long-term seizure freedom in frontal lobe epilepsy surgery	179
Correction to: Variants in the SK2 channel gene (KCNN2) lead to dominant neurodevelopmental movement disorders	178
Methodological drawbacks in the alleged association between foetal sonographic anomalies and autism	173
Proust and his neurologists: the challenge of functional disorders	170
Biallelic ADAM22 pathogenic variants cause progressive encephalopathy and infantile-onset refractory epilepsy	169
Genetically identical twin-pair difference models support the amyloid cascade hypothesis	168
Source-sink connectivity: a novel interictal EEG marker for seizure localization	163
De novo variants in ATXN7L3 lead to developmental delay, hypotonia and distinctive facial features	158
Gain-of-function and loss-of-function variants in GRIA3 lead to distinct neurodevelopmental phenotypes	153
3T MRI of rapid brain activity changes driven by subcallosal cingulate deep brain stimulation	152
Optogenetic stimulation of the superior colliculus suppresses genetic absence seizures	152
Brain repair mechanisms after cell therapy for stroke	148
The axon initial segment as a source of neuropathic pain	146
Clinical and genetic spectrum of 355 Chinese children with epilepsy: a trio-sequencing-based study	142
Choroid plexus mis-splicing and altered cerebrospinal fluid composition in myotonic dystrophy type 1	135
‘Seeding’ the idea of early diagnostics in synucleinopathies	133
Clinical and genetic characterization of a progressive RBL2-associated neurodevelopmental disorder	132
Deep brain stimulation: a tale of two targets … and closing the loop	131
Peripherin is a biomarker of axonal damage in Guillain-Barré syndrome: a pathophysiological annotation	128
Biallelic FRA10AC1 variants cause a neurodevelopmental disorder with growth retardation	124
We’re all in this together: a rejoinder to Masud Husain’s (rant) editorial	124
Distinct subcellular autophagy impairments in induced neurons from patients with Huntington's disease	123

Somatic variants of MAP3K3 are sufficient to cause cerebral and spinal cord cavernous malformations	123
Lesion correlates of impaired acoustic-phonetic perception after unilateral left hemisphere stroke	119
ActivatingRAC1variants in the switch II region cause a developmental syndrome and alter neuronal morphology	118
The vascular contribution of apolipoprotein E to Alzheimer’s disease	116
Brain cholesterol and Alzheimer's disease: challenges and opportunities in probe and drug development	111
Associations between accelerated forgetting, amyloid deposition and brain atrophy in older adults	110
From bugs to brain: unravelling the GABA signalling networks in the brain–gut–microbiome axis	106
‘Hippocampal innate inflammatory gliosis only’ in pharmacoresistant temporal lobe epilepsy	106
The use of optical coherence tomography in neurology: a review	103
Cerebral amyloid angiopathy interacts with neuritic amyloid plaques to promote tau and cognitive decline	101
Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer’s disease	100
Speech and language markers of neurodegeneration: a call for global equity	95
The inferior fronto-occipital fasciculus: bridging phylogeny, ontogeny and functional anatomy	90
Dysfunction of the magnocellular subdivision of the visual thalamus in developmental dyslexia	89
Imaging protein aggregates in the serum and cerebrospinal fluid in Parkinson’s disease	87
Trigeminal nerve microstructure is linked with neuroinflammation and brainstem activity in migraine	86
18F-MK-6240 tau-PET in genetic frontotemporal dementia	86
Dysregulated cortical excitability and tau phosphorylation in a β3 integrin mouse model of autism	86
Mapping the peripheral immune landscape of Parkinson’s disease patients with single-cell sequencing	86
Correction to: New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy	85
Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups	85
Hitching a ride on exosomes: a new approach for the delivery of siRNA-mediated therapies	85
A data-driven study of Alzheimer's disease related amyloid and tau pathology progression	85
Multiple sclerosis in Denmark (1950–2023): mean age, sex distribution, incidence and prevalence	84
Biallelic null variants in PNPLA8 cause microcephaly by reducing the number of basal radial glia	81
Reply: Unblinding in the lecanemab trial in Alzheimer’s disease	81
Clinically relevant mitochondrial-targeted therapy improves chronic outcomes after traumatic brain injury	81
Demystifying interictal discharges and seizure initiation in focal epilepsy	81
Multimodal mapping of regional brain vulnerability to focal cortical dysplasia	79
The three deceits of bureaucracy	79
Intravenous delivery of adeno-associated viral gene therapy in feline GM1 gangliosidosis	79
Integrative genomics reveals pathogenic mediator of valproate-induced neurodevelopmental disability	79
Extra-cranial cholinergic lesions in dementia with Lewy bodies	78
Cytotoxic T cells and plasma cells dominate early in temporal lobe epilepsy with GAD antibodies	77
Evolutionary perspectives on mRNA signatures of neurodegeneration-related brain remodelling	77
New mechanistic insights into hereditary spastic paraplegias	77
GGC repeat expansions in NOTCH2NLC cause uN2CpolyG cerebral amyloid angiopathy	76
Functional network reorganization precedes apathy in Parkinson’s disease: a neural marker of risk?	76
Stuttering associated with a pathogenic variant in the chaperone protein cyclophilin 40	75
The low dimensionality of post-stroke cognitive deficits: it’s the lesion anatomy!	75
Multiple lines of evidence for disruption of nuclear lamina and nucleoporins in FUS amyotrophic lateral sclerosis	74
Preclinical type 2 diabetes mellitus subtypes: new insights into diabetes, depression and dementia	74
Multicentre analysis of seizure outcome predicted by removal of high-frequency oscillations	73
How COVID-19 affects microvessels in the brain	73
Defective lipid signalling caused by mutations inPIK3C2Bunderlies focal epilepsy	72
Deciphering the impact of coding and non-coding SCN1A gene variants on RNA splicing	72
Hippocampal synaptic failure is an early event in experimental parkinsonism with subtle cognitive deficit	72
Extracellular vesicle biomarkers for complement dysfunction in schizophrenia	72
Multifaceted nanoparticles: emerging mechanisms and therapies in neurodegenerative diseases	72
Cross-seeding by prion protein inactivates TDP-43	71

Clinical and MRI measures to identify non-acute MOG-antibody disease in adults	70
A sensory neuron-specific long non-coding RNA reduces neuropathic pain by rescuing KCNN1 expression	70
The spectrum of disease and tau pathology of nodding syndrome in Uganda	69
Long-term neuropsychological trajectories in children with epilepsy: does surgery halt decline?	68
Loss-of-function variants inMYCBP2cause neurobehavioural phenotypes and corpus callosum defects	68
Loss of DOT1L disrupts neuronal transcription and leads to a neurodevelopmental disorder	66
Biallelic LGI1 and ADAM23 variants cause hippocampal epileptic encephalopathy via the LGI1–ADAM22/23 pathway	66
Synaptic dysregulation in a mouse model of GRIN2D developmental and epileptic encephalopathy	65
Midbrain cytotoxic T cells as a distinct neuropathological feature of progressive supranuclear palsy	65
Novel insight into TRPV1-induced mitochondrial dysfunction in neuropathic pain	65
Genome-wide association study of neuropathological features in Lewy body disease	64
A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings	63
Disruption of DNA methylation underpins the neuroinflammation induced by targeted CNS radiotherapy	63
BMP receptor blockade overcomes extrinsic inhibition of remyelination and restores neurovascular homeostasis	63
The interictal suppression hypothesis is the dominant differentiator of seizure onset zones in focal epilepsy	62
Structural covariance analysis for neurodegenerative and neuroinflammatory brain disorders	62
The neuroethics of disorders of consciousness: a brief history of evolving ideas	62
Integrative miRNA–mRNA profiling of human epidermis: unique signature of SCN9A painful neuropathy	62
Periventricular remyelination failure in multiple sclerosis: a substrate for neurodegeneration	60
Neural stem cell therapies for spinal cord injury repair: an update on recent preclinical and clinical advances	60
Correction to: Blood–brain barrier opening of the default mode network in Alzheimer's disease with magnetic resonance-guided focused ultrasound	59
Clinical features and prognostic factors in adults with brain abscess	59
How modular are modules in visual cortex?	58
Correction to: Sex-specific modulation of amyloid-β on tau phosphorylation underlies faster tangle accumulation in females	58
Amyloid-β predominant Alzheimer’s disease neuropathologic change	58
From shadows to spotlight: the evolution of migraine stigma since the 17th century	58
JC virus spread is potentiated by glial replication and demyelination-linked glial proliferation	57
Impaired value-based decision-making in Parkinson’s disease apathy	57
Early onset hereditary neuronopathies: an update on non-5qmotor neuron diseases	57
Nigrostriatal tau pathology in parkinsonism and Parkinson’s disease	56
Failure of C9orf72 sense repeat-targeting antisense oligonucleotides: lessons learned and the path forward	56
The human subthalamic nucleus transiently inhibits active attentional processes	56
Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer’s disease	56
Human lesions and animal studies link the claustrum to perception, salience, sleep and pain	56
Anatomo-functional basis of emotional and motor resonance elicited by facial expressions	55
Corrigendum to: Imaging protein aggregates in the serum and cerebrospinal fluid in Parkinson’s disease	54
Sorting out Parkinson’s disease: one cell at a time	54
Correction to: Expanded clinical phenotype spectrum correlates with variant function in SCN2A-related disorders	54
UNC13B and focal epilepsy	54
Startle responses in Duchenne muscular dystrophy: a novel biomarker of brain dystrophin deficiency	54
A novel eye-movement impairment in multiple sclerosis indicating widespread cortical damage	54
A journey towards the pot of gold	53
Untangling white matter fibre changes in Alzheimer's disease and small vessel disease	53
Reply: The correlation of behavioural deficits post-stroke: a trivial issue?	53
In silico versus functional characterization of genetic variants: lessons from muscle channelopathies	53
Neuromelanin as a nidus for neurodegeneration	52
A passive and objective measure of recognition memory in Alzheimer’s disease using Fastball memory assessment	52
Reply: Do we need new MRI criteria for the diagnosis of radiologically isolated syndrome?	52
Wheelchair use in genetically confirmed FSHD1 from a large cohort study in Chinese population	52
Delineation of functionally essential protein regions for 242 neurodevelopmental genes	52
Reply: Lecanemab: turning point, or status quo? An ethics perspective	52
Random forest: random results or meaningful insights for patients with facioscapulohumeral muscular dystrophy?	52
Neural basis of speech and grammar symptoms in non-fluent variant primary progressive aphasia spectrum	51
Repeat conformation heterogeneity in cerebellar ataxia, neuropathy, vestibular areflexia syndrome	51
Effort avoidance as a core mechanism of apathy in frontotemporal dementia	51
Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration	51
Sleep and seizure risk in epilepsy: bed and wake times are more important than sleep duration	51
Endosomal 2Cl−/H+ exchangers regulate neuronal excitability by tuning Kv7/KCNQ channel density	51
Occludin modulates HIV and ischaemic stroke response via mitochondrial antiviral signalling pathway	50
Multicompartmental models and diffusion abnormalities in paediatric mild traumatic brain injury	50
The lysosomal β-glucocerebrosidase strikes mitochondria: implications for Parkinson’s therapeutics	50
Interferon-γ controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder	50
Misdirected yet intact TREX1 exonuclease activity causes human cerebral and systemic small vessel disease	49
Imaging chronic active lesions in multiple sclerosis: a consensus statement	49
Genetic variability in sporadic amyotrophic lateral sclerosis	49
Widespread white matter oedema in subacute COVID-19 patients with neurological symptoms	49
Age-related and amyloid-beta-independent tau deposition and its downstream effects	49
How patients with multiple sclerosis acquire disability	49
Large-scale rare variant burden testing in Parkinson's disease	49
White matter connections within the central sulcus subserving the somato-cognitive action network	48
Recovery from aphasia in the first year after stroke	48
Basal forebrain integrity, cholinergic innervation and cognition in idiopathic Parkinson’s disease	48
Characterizing proteomic and transcriptomic features of missense variants in amyotrophic lateral sclerosis genes	48
Cdc42GAP deficiency contributes to the Alzheimer’s disease phenotype	48
Common and distinct fronto-striatal volumetric changes in heroin and cocaine use disorders	48
CGRP signalling in migraine: time to look downstream?	48
Motor compensation in Parkinson’s disease: an empirical challenge with clinical implications	47
Development of a novel tau propagation mouse model endogenously expressing 3 and 4 repeat tau isoforms	47
Is it time to rename hereditary cases of cerebral palsy?	47
Morc2a variants cause hydroxyl radical-mediated neuropathy and are rescued by restoring GHKL ATPase	47

Cul-4 inhibition rescues spastin levels and reduces defects in hereditary spastic paraplegia models	47
Bridging the gaps between JCV infection models and human disease	46
Correction to: Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates	46
Biomarker evidence of neurodegeneration in mid-life former rugby players	45
Motor network gamma oscillations in chronic home recordings predict dyskinesia in Parkinson’s disease	45
ZSCAN10 deficiency causes a neurodevelopmental disorder with characteristic oto-facial malformations	45
Anterior optic pathway pathology in CNS demyelinating diseases	45
Emotional bias modification weakens game-related compulsivity and reshapes frontostriatal pathways	45
The ageing central nervous system in multiple sclerosis: the imaging perspective	44
Four dimensions of naturalistic language production in aphasia after stroke	44
The visual cortex in the blind but not the auditory cortex in the deaf becomes multiple-demand regions	44
Thalamic stereo-EEG in epilepsy surgery: where do we stand?	44
Tiam1 is part of a novel mechanism for morphine tolerance and hyperalgesia	44
Stimulation of frontal pathways disrupts hand muscle control during object manipulation	44
Shedding light on a novel circuit within primary motor cortex as a target for neuromodulation	44
Localizing epileptogenic tissues in epilepsy: are we losing (the) focus?	43
PTPA variants and the risk for Parkinson’s disease in diverse ancestry populations	43
Imbalanced basal ganglia connectivity is associated with motor deficits and apathy in Huntington’s disease	43
In vitro ictogenesis is stochastic at the single neuron level	43
Synaptic and cognitive impairment associated with L444P heterozygous glucocerebrosidase mutation	43
Broad activation of the Parkin pathway induces synaptic mitochondrial deficits in early tauopathy	43
Alzheimer proteopathic tau seeds are biochemically a forme fruste of mature paired helical filaments	43
Decomposing MRI phenotypic heterogeneity in epilepsy: a step towards personalized classification	42
Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis	42
Amyloid-β-activated microglia can induce compound proteinopathies	42
Smarter adaptive platform clinical trials in neurology	42
Interleukin-17B is a new biomarker of human muscle regeneration in dystrophinopathies	41
The functional role of the precuneus	41
Diffusely abnormal white matter converts to T2 lesion volume in the absence of MRI-detectable acute inflammation	41
Brain accumulation of lactosylceramide characterizes GALC deficiency in a zebrafish model of Krabbe disease	41
Seeding, maturation and propagation of amyloid β-peptide aggregates in Alzheimer’s disease	41
C-terminal TMEM106B fragments in human brain correlate with disease-associated TMEM106B haplotypes	41
Understanding brain calcification via N-terminal acetylation at the Golgi apparatus	41
The basal forebrain cholinergic system as target for cell replacement therapy in Parkinson’s disease	41
Resting-state EEG reveals four subphenotypes of amyotrophic lateral sclerosis	41
Interpretable surface-based detection of focal cortical dysplasias: a Multi-centre Epilepsy Lesion Detection study	41
Reply: An epigenetic basis for genetic anticipation in facioscapulohumeral muscular dystrophy type 1	40
One transgene, two myopathies: an MTM1 ‘cross gene therapy’ for BIN1 deficiency?	40
Chasing MOG antibodies down … assays and lumbar punctures	40
Ockham’s razor, not a barber’s weapon but a writer’s tool	40
Corrigendum to: Myopathic mitochondrial DNA depletion syndrome associated with biallelic variants in LIG3	40
The BS variant of C4 protects against age-related loss of white matter microstructural integrity	40
Reply: Methodological drawbacks in the alleged association between foetal sonographic anomalies and autism	40
Reply: The challenge of assessing invasive biomarkers for epilepsy surgery and To plan efficacious epilepsy surgery	40
Right temporal degeneration and socioemotional semantics: semantic behavioural variant frontotemporal dementia	40
TGFβ4 alleviates the phenotype of Charcot–Marie–Tooth disease type 1A	40
Poor statistical reporting in a spinal cord injury clinical trial	40
Plasma biomarkers in chronic single moderate/severe traumatic brain injury	39
Motivational and cognitive predictors of apathy after subthalamic nucleus stimulation in Parkinson’s disease	39
Of networked lesions and lesioned networks	39
Neurophysiological consequences of synapse loss in progressive supranuclear palsy	39
Great science does not communicate itself: but who should and how?	39
Reply: Putative benefits of vitamin D supplements in multiple sclerosis out of reach due to sample size	39
Role of pattern recognition receptors in chemotherapy-induced neuropathic pain	39
Direct electrical brain stimulation of human memory: lessons learnt and future perspectives	38
Neurovascular injury with complement activation and inflammation in COVID-19	38
Uncovering the distinct macro-scale anatomy of dysexecutive and behavioural degenerative diseases	38
Dopamine and deep brain stimulation accelerate the neural dynamics of volitional action in Parkinson's disease	38
Intra-putaminal muscarinic receptor agonist infusion induces a dystonic phenotype in non-human primate	38
Myelination potential and injury susceptibility of grey versus white matter human oligodendrocytes	38
An extended amygdala circuit at the core of long-term post-sepsis psychiatric disorders	38
Functional connectivity drives stroke recovery: shifting the paradigm from correlation to causation	38
Spreading depolarizations in ischaemia after subarachnoid haemorrhage, a diagnostic phase III study	38
Limitation of life sustaining therapy in disorders of consciousness: ethics and practice	38
Increase of HCN current in SOD1-associated amyotrophic lateral sclerosis	37
Genome-wide epistasis analysis reveals significant epistatic signals associated with Parkinson’s disease risk	37
Noradrenergic alterations in Parkinson’s disease: a combined 11C-yohimbine PET/neuromelanin MRI study	37
Dynamic reorganization of task-related network interactions in post-stroke aphasia recovery	37
Analysing an allelic series of rare missense variants of CACNA1I in a Swedish schizophrenia cohort	37
Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine	37
Mitochondrial dynamics and bioenergetics in Alzheimer’s induced pluripotent stem cell-derived neurons	37
Ligand-free mitochondria-localized mutant AR-induced cytotoxicity in spinal bulbar muscular atrophy	37
Medial temporal lobe structural changes when Down syndrome and Alzheimer’s disease collide	37
The Wernicke conundrum revisited: evidence from connectome-based lesion-symptom mapping	37
Clinical features and prognostic factors in adults with viral meningitis	37
Clinicopathological correlates in the frontotemporal lobar degeneration–motor neuron disease spectrum	37
Interaction of motor behaviour, cortical oscillations and deep brain stimulation in Parkinson’s disease	37
Nifuroxazide rescues the deleterious effects due to CHCHD10-associated MICOS defects in disease models	37
Reply: Neural substrates of the link between dual-task gait and dementia: an intermediary step in which direction?	37
Brainstem cavernous malformations: observation, microsurgical resection or stereotactic radiosurgery	37
Cation leak through the ATP1A3 pump causes spasticity and intellectual disability	36
Defining repetitive behaviours in frontotemporal dementia	36
Heterozygous PRKN mutations are common but do not increase the risk of Parkinson’s disease	36
Seronegative autoimmune encephalitis: clinical characteristics and factors associated with outcomes	36
Predictors of functional outcomes in patients with facioscapulohumeral muscular dystrophy	36
Phenoconversion in pure autonomic failure: a multicentre prospective longitudinal cohort study	36
The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis	36
Genome-wide contribution of common short-tandem repeats to Parkinson’s disease genetic risk	35
Bobby Fischer and the delusions of a king of logic	35
Expedited epilepsy surgery prior to drug resistance in children: a frontier worth crossing?	35
Multimodal layer modelling reveals in vivo pathology in amyotrophic lateral sclerosis	35
Can immunological imprinting drive neurological dysfunction in long COVID?	35
Mitochondrial damage is associated with an early immune response in inclusion body myositis	35
Correction to: TMEM63C mutations cause mitochondrial morphology defects and underlie hereditary spastic paraplegia	35
Reply: Poor statistical reporting in a spinal cord injury clinical trial	35